AstraZeneca is advancing its oral GLP-1 drug into Phase III trials while defending dapagliflozin patents in Australia. The company obtained an Australian court injunction against a generic competitor and has partnered with Evinova to use AI for clinical trials. India could be a future market for the oral GLP-1 drug pending global trial data.
The Delhi High Court ruled Dr. Reddy's can export semaglutide, finding Novo Nordisk's patent unenforceable. Dr. Reddy's plans to launch generic Wegovy at 60% discount pending approval.
The FDA announced new enforcement priorities on February 6, 2026, to restrict GLP-1 active pharmaceutical ingredients used in non-FDA-approved compounded drugs being mass-marketed. The action follows an August 2025 citizens' petition arguing that large-scale compounded semaglutide production poses public health risks including lack of immunogenicity assessments and misleading marketing practices.
Recent research highlights advances in precision medicine for psoriatic arthritis, including a biopsy-driven treatment strategy that improved clinical outcomes and ongoing investigation into new biologic agents, combinations, and biomarker panels.
The life sciences industry expects strong growth in 2026 driven by AI adoption and GLP-1 drug innovations, but faces headwinds from tariffs, FDA changes, and rising shareholder activism. Over 320 public activist campaigns have targeted life sciences companies since 2020, with 75-80% of biotech and pharma targets being pre-revenue firms.
The FDA has approved Pfizer's BRAFTOVI for BRAF V600E metastatic colorectal cancer and VEPPANU for ESR1 mutated breast cancer. The oncolytic virus cancer therapy pipeline expands with over 120 companies developing 125+ drugs. Positive late-stage data for other Pfizer oncology programs was also reported.
Delaware's state employee health plan may raise GLP-1 copays from $32 to $120 per month or eliminate weight-loss drug coverage entirely, as costs are projected to reach $211 million by 2029. A decision is expected February 23, 2027.
BrightGene Bio-Medical reported Phase III data for BGM0504 showing 19.3% mean weight reduction and improvements in blood pressure, lipids and uric acid. The data highlighted GIP as a key variable in broader metabolic management.
An experimental gut procedure helped a small group of patients maintain up to 80% of weight loss after stopping tirzepatide. A larger trial involving more than 300 people is underway.
GLP-1 drugs used for type 2 diabetes and obesity are seeing rising demand for weight loss as safety concerns also draw attention. A 2025 WHO guideline said long-term safety data remains limited.
